MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF metastatic colorectal cancer
-
Published:2022-10
Issue:5
Volume:7
Page:100559
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Tabernero J.ORCID,
Grothey A.,
Arnold D.,
de Gramont A.,
Ducreux M.,
O’Dwyer P.,
Tahiri A.,
Gilberg F.,
Irahara N.,
Schmoll H.-J.,
Van Cutsem E.
Subject
Cancer Research,Oncology
Reference21 articles.
1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016
2. National Comprehensive Cancer Network. Colon cancer, version 2, 2021;Benson;J Natl Compr Canc Netw,2021
3. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial;Johnsson;Ann Oncol,2013
4. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group;Simkens;Lancet,2015
5. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial;Hegewisch-Becker;Lancet Oncol,2015
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献